NCT03456102View on ClinicalTrials.gov

Statin Adjunctive Therapy for TB

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 9, 2020

Primary Completion Date

August 31, 2022

Study Completion Date

August 31, 2022

Conditions
Tuberculosis
Interventions
DRUG

Pravastatin

"Phase IIB clinical trial: A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated.~A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated."

Trial Locations (1)

Unknown

Chris Hani Baragwanath Hospital, Johannesburg

All Listed Sponsors
lead

Johns Hopkins University

OTHER

NCT03456102 - Statin Adjunctive Therapy for TB | Biotech Hunter | Biotech Hunter